Moderna (MRNA) Stock Forecast & Price Target $27.16 -1.19 (-4.20%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$26.82 -0.34 (-1.27%) As of 08:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Moderna - Analysts' Recommendations and Stock Price Forecast (2025) How MarketBeat Calculates Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Consensus Rating HoldBased on 24 Analyst RatingsSell4Hold16Buy4 Based on 24 Wall Street analysts who have issued ratings for Moderna in the last 12 months, the stock has a consensus rating of "Hold." Out of the 24 analysts, 4 have given a sell rating, 16 have given a hold rating, 3 have given a buy rating, and 1 has given a strong buy rating for MRNA. Consensus Price Target $59.00117.23% Upside According to the 24 analysts' twelve-month price targets for Moderna, the average price target is $59.00. The highest price target for MRNA is $179.00, while the lowest price target for MRNA is $27.00. The average price target represents a forecasted upside of 117.23% from the current price of $27.16. Get the Latest News and Ratings for MRNA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Moderna and its competitors. Enter your email to sign up for newsletter Sign Up MRNA Analyst Ratings Over TimeTypeCurrent Forecast4/2/24 to 4/2/251 Month Ago3/3/24 to 3/3/253 Months Ago1/3/24 to 1/2/251 Year Ago4/3/23 to 4/2/24Strong Buy1 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)0 Strong Buy rating(s)Buy3 Buy rating(s)3 Buy rating(s)5 Buy rating(s)5 Buy rating(s)Hold16 Hold rating(s)15 Hold rating(s)12 Hold rating(s)9 Hold rating(s)Sell4 Sell rating(s)4 Sell rating(s)4 Sell rating(s)2 Sell rating(s)Consensus Price Target$59.00$60.63$79.50$129.82Forecasted Upside117.23% Upside100.30% Upside89.29% Upside25.30% UpsideConsensus RatingHoldHoldHoldHold Remove Ads MRNA Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History MRNA Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Moderna Stock vs. The CompetitionTypeModernaMedical CompaniesS&P 500Consensus Rating Score 2.04 2.82 2.54Consensus RatingHoldModerate BuyModerate BuyPredicted Upside117.23% Upside19,857.32% Upside19.03% UpsideNews Sentiment RatingNeutral NewsSee Recent MRNA NewsPositive NewsPositive News Remove Ads Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails3/21/2025JPMorgan Chase & Co.3 of 5 starsJessica FyeSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower TargetUnderweight ➝ Underweight$40.00 ➝ $33.00+2.21%3/13/2025Citigroup3 of 5 starsGeoff MeachamSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$40.00+14.25%2/19/2025UBS Group4 of 5 starsEliana MerleSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower TargetBuy ➝ Buy$96.00 ➝ $78.00+115.77%2/18/2025Royal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLuca IssiSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$40.00 ➝ $40.00+11.97%2/18/2025BarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingGena WangSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$111.00 ➝ $45.00+36.40%2/14/2025Evercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingCory KaimovSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Target$50.00+40.73%2/11/2025Bank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingTim AndersonSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower TargetUnderperform ➝ Underperform$41.00 ➝ $34.00+6.68%1/29/2025The Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSalveen RichterSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$99.00 ➝ $51.00+13.48%1/16/2025Leerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetUnderweight ➝ Underweight$31.00 ➝ $27.00-19.99%1/16/2025Berenberg BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingH. GillisSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost TargetHold ➝ Hold$33.00 ➝ $42.00+24.46% Get the Latest News and Ratings for MRNA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter. 1/15/2025Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingMatthew HarrisonSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower TargetEqual Weight ➝ Equal Weight$70.00 ➝ $38.00+8.57%12/18/2024ArgusSubscribe to MarketBeat All Access for the recommendation accuracy ratingJ. HellwegSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold11/18/2024Hsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingY. LiuSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy11/18/2024Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOverweight ➝ Overweight$115.00 ➝ $69.00+76.83%11/18/2024HSBCSubscribe to MarketBeat All Access for the recommendation accuracy rating UpgradeHold ➝ Buy$58.00+57.39%11/15/2024Wolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingA. HammondSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform$40.00+0.58%11/8/2024Needham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingHold10/17/2024Sanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingC. BreenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform$55.00-4.28%10/15/2024Jefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetHold ➝ Hold$65.00 ➝ $55.00-4.75%9/13/2024TD CowenSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetHold ➝ Hold$70.00 ➝ $60.00-9.92%9/13/2024OppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeOutperform ➝ Market Perform8/7/2024Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy rating UpgradeSell ➝ Hold$85.00 ➝ $80.00-2.79%6/27/2024William BlairSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingMarket Perform5/3/2024Canaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetHold ➝ Hold$91.00 ➝ $106.00-15.20%6/26/202351jobSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingUpgrade4/25/2023GuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageNeutralAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:48 AM ET. Should I Buy Moderna Stock? MRNA Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, March 20, 2025. Please send any questions or comments about these Moderna pros and cons to contact@marketbeat.com. Moderna Bull Case Here are some ways that investors could benefit from investing in Moderna, Inc.: Moderna, Inc. has a strong focus on messenger RNA therapeutics and vaccines, which are at the forefront of biotechnology innovation, potentially leading to significant market opportunities. The company has recently seen a notable increase in stock purchases by its CEO, indicating confidence in the company's future performance and potential for growth. Current stock price is around $40.00, which may present a buying opportunity for investors looking for value in the biotechnology sector. Moderna's diverse pipeline includes treatments for infectious diseases and immuno-oncology, which could lead to multiple revenue streams and reduce reliance on any single product. Analysts have given a consensus target price of $59.60, suggesting potential upside from the current trading levels, which could attract investors looking for growth. Moderna Bear Case Investors should be bearish about investing in Moderna, Inc. for these reasons: Recent downgrades from several brokerages, including Barclays and Argus, indicate a cautious outlook on the stock, which may signal potential risks for investors. The stock has received four sell ratings from analysts, suggesting that a significant portion of the market may have a negative view on its future performance. Price targets have been lowered by multiple firms, with some estimates dropping to as low as $34.00, which could reflect concerns about the company's growth prospects. Moderna's reliance on the success of its mRNA technology means that any setbacks in clinical trials or regulatory approvals could adversely affect its stock price. With a high number of hold ratings (sixteen), there may be a lack of strong bullish sentiment in the market, which could limit upward momentum for the stock. MRNA Forecast - Frequently Asked Questions What is Moderna's forecast for 2025? According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Moderna is $59.00, with a high forecast of $179.00 and a low forecast of $27.00. Should I buy or sell Moderna stock right now? 24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last twelve months. There are currently 4 sell ratings, 16 hold ratings, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares. Does Moderna's stock price have much upside? According to analysts, Moderna's stock has a predicted upside of 117.23% based on their 12-month stock forecasts. Has Moderna been downgraded by Wall Street analysts recently? Over the previous 90 days, Moderna's stock had 2 downgrades by analysts. What analysts cover Moderna? Moderna has been rated by research analysts at Bank of America, Barclays, Berenberg Bank, Citigroup, Evercore ISI, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Royal Bank of Canada, The Goldman Sachs Group, and UBS Group in the past 90 days. Do Wall Street analysts like Moderna more than its competitors? Analysts like Moderna less than other "medical" companies. The consensus rating for Moderna is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MRNA compares to other companies. Stock Forecasts and Research Tools Related Companies ARGX Stock Forecast ONC Stock Forecast BNTX Stock Forecast TEVA Stock Forecast SMMT Stock Forecast ITCI Stock Forecast GMAB Stock Forecast RDY Stock Forecast VTRS Stock Forecast ASND Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:MRNA) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moderna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moderna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.